Skip to main content

Table 3 Change from baseline and treatment differences (glycopyrronium vs tiotropium) in IC at all time points evaluated on Day 1 and Week 12 (PPS)

From: A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

  LSM (95% CI) treatment difference glycopyrronium versus tiotropium Mean (SD) change from baseline (L)
Time point Glycopyrronium (N = 300) Tiotropium (N = 293)
Day 1    
   25 min 0.078 (0.033,0.123)* 0.242 (0.252) 0.166 (0.236)
   2 h 0.098 (0.045,0.152)* 0.298 (0.304) 0.197 (0.268)
   4 h 0.035 (−0.021,0.090) 0.234 (0.284) 0.198 (0.307)
   24 h 0.004 (−0.050,0.057) 0.117 (0.293) 0.111 (0.281)
Week 12    
   −20 min −0.029 (−0.097,0.038) 0.087 (0.369) 0.099 (0.355)
   25 min 0.012 (−0.054,0.079) 0.211 (0.365) 0.187 (0.345)
   2 h 0.055 (−0.014,0.124) 0.266 (0.368) 0.207 (0.385)
   4 h 0.037 (−0.033,0.107) 0.233 (0.371) 0.186 (0.367)
   24 h −0.034 (−0.101,0.033) 0.126 (0.357) 0.148 (0.360)
  1. IC = inspiratory capacity; SD = standard deviation; LSM = least squares mean; CI = confidence interval; *p < 0.001. There were no other statistically significant differences at any other time point measured.